Arven Pharmaceuticals is an R&D based high-tech pharmaceutical company with a focus on research and development, manufacturing and marketing of high-tech pharmaceutical products, including biotech drugs and multi-dose innovative devices for dry powder inhalers.
Abdi İbrahim was founded in 1912 and has been the leader of Turkey’s Pharmaceutical Industry for 17 years, and boasts the largest product portfolio in the sector, with more than 200 brands and over 450 products.
MANAGING DIRECTOR, GENERAL MANAGER & BUSINESS STRATEGY CONSULTANT, HASBIOTECH
Founded in 2009, Hasbiotech is driven to create and manufacture an original Turkish medicine starting from scratch and is establishing a manufacturing site for local production of biotechnological products.
Tüm Ekip Pharmaceuticals was established in 2000 and is a specialized injectable pharmaceutical producer, with capability to produce seven different sterile forms.
Centurion Pharma was founded in 1979, and today imports products for the treatment of rare diseases as well as biological, biotechnological and hospital products. Centurion has also taken steps to develop and manufacture products locally by establishing an R&D Department in 2011.
Sanofi has a diversified portfolio, ranging from innovative medicines including rare diseases, immunology, diabetes and cardiovascular to consumer healthcare products and vaccines.
CHIEF SENIOR RESEARCHER, TUBITAK MAM, GENETIC ENGINEERING AND BIOTECHNOLOGY INSTITUTE (GEBI)
The Genetic Engineering and Biotechnology Institute (GEBI) conducts researches and develops technologies in the field of genetic engineering and biotechnology with high added value by taking into consideration the developments in the world and the needs of the public and industrial sectors in Turkey.
TR-PHARM, founded in 2013, is a marketer of pharmaceuticals and biopharmaceuticals with a focus on high-tech R&D and the ambition to gain global recognition in bringing high-quality and cost-effective solutions in the healthcare industry.
MACIG 2025 - Mining in Africa Country Investment Guide
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.